Hormonal Therapy News and Research RSS Feed - Hormonal Therapy News and Research

Hormonal Therapy is treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the body’s natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone. Also called endocrine therapy, hormone therapy, and hormone treatment.
Researchers to develop new test to predict therapy for women with ER+ breast cancer

Researchers to develop new test to predict therapy for women with ER+ breast cancer

Researchers from Case Western Reserve University are teaming with industry and other academics to develop a quick and inexpensive test to predict which women with ER+ breast cancer need chemotherapy and which need only the more tolerable hormonal therapy. [More]
Intrinsic subtyping of breast cancer can aid prognosis, treatment of tumor patients

Intrinsic subtyping of breast cancer can aid prognosis, treatment of tumor patients

Published in JAMA Oncology, Principal Investigator of Vall d´Hebron Institute of Oncology´s Translational Genomics Group, Team Leader of translational genomics and targeted therapeutics in solid tumors at the August Pi I Sunyer Biomedical Research Institute, and Head of Medical Oncology at the Hospital Clínic in Barcelona, Aleix Prat has led a study showing the intrinsic subtyping of breast cancer by means of a genomic test as the most important prognostic factor in advanced or metastatic hormone-sensitive breast cancer. [More]
New research reveals advances that could change gynecologic cancer standard-of-care treatments

New research reveals advances that could change gynecologic cancer standard-of-care treatments

Advances that could change gynecologic cancer standard-of-care treatments are the centerpiece of key studies being presented by researchers from The University of Texas MD Anderson Cancer Center's Department of Gynecologic Oncology and Reproductive Medicine at the 2016 Annual Meeting of the American Society of Clinical Oncology. [More]
Mastectomy followed by standard therapy improves survival in stage IV breast cancer patients

Mastectomy followed by standard therapy improves survival in stage IV breast cancer patients

Surgery to remove the primary tumor in women diagnosed with stage IV breast cancer, followed by the standard combination of therapies, adds months to the patients' lives, compared with standard therapy alone, an international clinical trial led by a University of Pittsburgh Cancer Institute professor revealed. [More]
Researchers spot molecular key that breast cancer cells use to invade bone marrow

Researchers spot molecular key that breast cancer cells use to invade bone marrow

Scientists at the Duke Cancer Institute have identified a molecular key that breast cancer cells use to invade bone marrow in mice, where they may be protected from chemotherapy or hormonal therapies that could otherwise eradicate them. [More]
Multi-gene test can help identify early breast cancer patients who can safely be spared chemotherapy

Multi-gene test can help identify early breast cancer patients who can safely be spared chemotherapy

Researchers have shown for the first time that it is possible to use a multi-gene test to identify patients with early breast cancer who can be spared chemotherapy and who will still be alive and well five years after diagnosis. [More]
Delivering microRNAs in cancer treatment: an interview with Dr Conde and Prof Artzi

Delivering microRNAs in cancer treatment: an interview with Dr Conde and Prof Artzi

microRNAs (miRs) are small endogenous noncoding RNA molecules (20–23 nucleotides) derived from imperfectly paired hairpin RNA structures naturally encoded in the genome that act specifically as triggering molecules to control translational repression or mRNA degradation. [More]
Pfizer’s IBRANCE (palbociclib) now approved for use in women with HR+, HER2- metastatic breast cancer

Pfizer’s IBRANCE (palbociclib) now approved for use in women with HR+, HER2- metastatic breast cancer

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy. [More]
Women suffering from blood clots can safely take hormone replacement therapy with anticoagulants

Women suffering from blood clots can safely take hormone replacement therapy with anticoagulants

New research published online today in Blood, the Journal of the American Society of Hematology (ASH), is the first to demonstrate that women on blood thinners can take estrogen-containing contraception or hormone replacement therapy without an increased risk of blood clots or uterine bleeding. [More]
Active surveillance may be a viable treatment for select DCIS patients

Active surveillance may be a viable treatment for select DCIS patients

Active surveillance could be a viable alternative to surgery and radiation for select patients with ductal carcinoma in situ, or DCIS, according to a mathematical model developed by researchers at Duke University. [More]
Combination treatment provides effective one-two punch against prostate cancer

Combination treatment provides effective one-two punch against prostate cancer

Results from a long-term clinical trial conducted by cancer researchers at Houston Methodist Hospital show that combining radiation treatment with "suicide gene therapy," a technique in which prostate cancer cells are genetically modified so they signal a patient's immune system to attack them, provides a safe and effective one-two punch against the disease. [More]
Uninsured, low-income breast cancer patients less likely to continue hormonal therapy

Uninsured, low-income breast cancer patients less likely to continue hormonal therapy

A University of Colorado Cancer Center study published in the journal Breast Cancer Research and Treatment shows that breast cancer patients whose health insurance plans included prescription drug benefits were 10 percent more likely to start important hormonal therapy than patients who did not have prescription drug coverage. [More]
Discrimination leads to dangerous health consequences among transgender Americans

Discrimination leads to dangerous health consequences among transgender Americans

Despite a surge in public attention toward the transgender population, transgender adults continue to face both major and daily discrimination that often directly leads to dangerous health consequences. [More]
Tailorx trial data supports use of Oncotype DX test in patients with early stage breast cancer

Tailorx trial data supports use of Oncotype DX test in patients with early stage breast cancer

Initial results were announced today from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early stage breast cancer sponsored by the National Cancer Institute, part of the National Institutes of Health, and led by the ECOG-ACRIN Cancer Research Group with support from Genomic Health, Inc. [More]
Hormonal therapy may protect women's ovaries, increase chances of pregnancy after breast cancer treatment

Hormonal therapy may protect women's ovaries, increase chances of pregnancy after breast cancer treatment

Young women undergoing chemotherapy for breast cancer may be more likely to remain fertile if they also receive hormonal treatment, according to new research presented to the 2015 European Cancer Congress on Monday and published simultaneously in Annals of Oncology. [More]
BWH, DFCI researchers receive $10 million to test effectiveness of aspirin in women with breast cancer

BWH, DFCI researchers receive $10 million to test effectiveness of aspirin in women with breast cancer

Researchers from Brigham and Women's Hospital and Dana-Farber Cancer Institute have received a $10 million Breakthrough Award from the Department of Defense's Office of the Congressionally Directed Medical Research Program to test whether aspirin helps women with breast cancer avoid recurrence and live longer. [More]
New assessment tool under development can help detect physical traits of Klinefelter syndrome

New assessment tool under development can help detect physical traits of Klinefelter syndrome

Klinefelter syndrome is the most common disorder of the male sex chromosomes, yet is rarely diagnosed in children. A new assessment tool is being developed by researchers at Columbia University Medical Center (CUMC) to help pediatricians detect the physical traits of the syndrome. The tool could pave the way for early interventions that prevent and treat a range of physical, psychological, social, and cognitive impairments. [More]
Education intervention can improve physicians’ understanding of transgender issues

Education intervention can improve physicians’ understanding of transgender issues

The term "transgender" has made its way into mainstream media thanks to Caitlyn Jenner, previously known as Bruce Jenner, who came out as a transgender woman earlier this year. [More]
Study: Breast cancer survivors experience post-treatment weight gain compared with cancer-free peers

Study: Breast cancer survivors experience post-treatment weight gain compared with cancer-free peers

Among women with a family history of breast cancer, those diagnosed with breast cancer gained weight at a greater rate compared with cancer-free women of the same age and menopausal status. [More]
International study provides evidence of clear link between smoking and risk of prostate cancer

International study provides evidence of clear link between smoking and risk of prostate cancer

Smoking is a known risk factor for the development of various forms of cancer. However, when it comes to the link between smoking and prostate cancer, the findings of previous studies have been contradictory. Now, for the first time, an international study led by MedUni Vienna and Basle University Hospital, has provided evidence of a clear link. [More]
Advertisement
Advertisement